Antibacterial Agents TRIZ Cases

Polymeric imidazolium compounds deliver rapid antimicrobial protection through electrostatic interactions with microbial cell surfaces.

Acidic finafloxacin formulation overcomes quinolone resistance in otic infections while minimizing inner ear toxicity.

Str-INP-1 bacteriophage isolates pathogenic bacteria via segmentation, avoiding antibiotic resistance and environmental pollution.

Low-dose compounds of formula I potentiate existing antimicrobials to overcome resistance mechanisms while reducing toxicity constraints.

Sulfonamide derivatives target bradykinin B1 receptors to reduce side effects from non-selective B2 blockade.

Blockmir oligonucleotides target the VE-cadherin mRNA 3'UTR to inhibit miR-27a binding, resolving off-target effects common in antisense therapies.

Nanoparticles penetrate bacterial biofilms to release antimicrobial agents locally, reducing toxicity and resistance risks.

An ATP-hydrolyzing enzyme degrades extracellular ATP to restore microbiome balance.

Novel lactams with heteroaryl substituents replace bromine to resolve cytotoxicity while maintaining antibacterial efficacy against biofilms.

Emergency information service manages multiple communication modes via user profiles to resolve PSAP operator complexity.

PD-1 antibodies block immunosuppressive pathways to enhance immune responses against cancer and chronic infections.

Targeted bacteriophages lyse pathogenic gut bacteria without disrupting the microbiome balance, avoiding antibiotic resistance.

Small molecule saponins replace costly macromolecular antibodies to lower production costs while maintaining stable PD-1 blocking efficacy.

Segmented S100A1 motifs restore cardiac contractility by improving sarcoplasmic reticulum calcium handling without gene therapy risks.

Thixotropic Carbopol ETD 2020 reduces viscosity for spraying then regains thickness to prevent running, resolving propellant compatibility issues.

Synthetic disulfide bonds stabilize CbpA R21 and R22 loop polypeptides, resolving low immunogenicity in children under two by inducing robust immune responses.

Spirocyclic compounds inhibit CGRP receptor binding, resolving limited efficacy in existing treatments.

Nanostructured lipid carriers deliver bactericidal activity against Helicobacter pylori.

Specific compounds resolve the trade-off between receptor targeting precision and broad therapeutic versatility across infectious and autoimmune diseases.

Blocking the Neuropilin-1 and Semaphorin axis with antibodies enhances anti-tumor immunity by destabilizing regulatory T cells in the tumor microenvironment.

Birinapant bivalent Smac mimetic antagonizes cIAP proteins to induce apoptosis, clearing persistent HIV infection while minimizing collateral host cell damage.

Boronic acid compounds reduce cytokine release to treat inflammatory diseases while minimizing side effects from conventional immunosuppressants.

Acylation of epigallocatechin gallate improves metabolic stability and safety against bacterial strains.

Beta-glucan administration primes immune resilience against upper respiratory tract infections during heavy training stress.

7-amino-azepin-substituted imidazopyridines boost iNOS inhibitory activity to resolve insufficient potency in prior pharmaceutical compositions.

Site-directed mutagenesis of alpha1 proteinase inhibitor alters receptor binding to mobilize specific hematopoietic cell subsets.

Extracting immunogenic epitopes from the full-length toxin eliminates liver damage risks while maintaining effective immune coverage against atrophic rhinitis.

Chromatography separates labeled complexes to measure drug ratios, optimizing therapy while reducing toxicity.

Novel polypeptides induce angiogenesis and provide antibacterial activity for wound treatment.

Tregitope peptides activate regulatory T cells to suppress autoimmune reactions while preserving infection defense mechanisms.

Formula I compounds inhibit tyrosine kinases to treat cell proliferation disorders, addressing palliative chemotherapy limitations.

Microcrystalline and carboxymethylcellulose mediate flavor delivery in high water dentifrices, preventing silica adsorption.

Local modifications to apramycin prevent AAC(3)-IV enzyme inactivation while maintaining low toxicity against resistant pathogens.

ACC2 inhibitors alter host cell metabolic parameters to reduce mycobacterial replication rates, addressing drug resistance and long therapy durations.

Solid daptomycin compositions with sucrose enable rapid reconstitution in aqueous diluents.

Extensive in vitro passaging converts virulent Mycoplasma bovis into safe, immunogenic vaccine strains that reduce clinical symptoms by over 50%.

Tricyclic ring system compounds treat resistant bacterial strains while reducing cytotoxicity.

A hydrophilic active ingredient associates with solid porous microcarriers featuring a hydrophobic surface, then disperses within a delivery agent.

Interferor peptides induce stable intermolecular beta-aggregate formation through specific aggregation-inducing sequences flanked by breaking residues.

A pMyong2 vector system drives high-level HIV-1 p24 antigen production in recombinant Mycobacterium bovis BCG strains.

Cycloalkyl-substituted quinuclidine esters reduce systemic side effects while maintaining local efficacy in respiratory treatments.

Sequential solvent treatment and repeated crystallization achieve 99% purity, resolving the trade-off between manufacturing precision and commercial viability.

In silico system replaces qualitative assays with quantitative stability data to resolve scale limitations in T-cell epitope identification.

Janthinobacterium lividum metabolites minimize fungal infections despite heat intolerance and inadequate cell density at skin temperatures.

Disinfecting composition uses N-acylated amino acids and non-ethoxylated anionic surfactants to destroy microorganisms on surfaces.